In an interview with PharmaShots, Dr. David Kendall, Senior Global Medical Advisor at Zealand Pharma shared his views on the availability of Zegalogue in the US for severe hypoglycemia in […]readmore
Authored by Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi Over the past few decades, progress in understanding the molecular drivers of disease has revealed exciting new […]readmore
In an interview with PharmaShots, Dr. Philip Mease, MD, Seattle Rheumatology Associates shares insights on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in The Lancet Rheumatology Shots: The […]readmore
In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I […]readmore
In an interview with PharmaShots, Dr. Dale Christensen, Ph.D., Director of Clinical Development at TFF Pharmaceuticals shared his views on the preliminary data from the P-I trial of inhalable tacrolimus […]readmore
In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment […]readmore
In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of […]readmore
In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor’s approval in the EU for patients with […]readmore
In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA’s Orphan Drug Designation (ODD) to Tesomet for the treatment of hypothalamic […]readmore
Introduction: “Over-prescription” is defined as the action of prescribing a drug or treatment in greater amount or on more occasions than necessary. Overprescribing, in general in health care, has been […]readmore